184 results on '"Scorletti, Eleonora"'
Search Results
2. Markers of adipose tissue fibrogenesis associate with clinically significant liver fibrosis and are unchanged by synbiotic treatment in patients with NAFLD
3. Lipid droplets in steatotic liver disease
4. Deep metabolic phenotyping of humans with protein-altering variants in TM6SF2 using a genome-first approach
5. A missense variant in human perilipin 2 (PLIN2 Ser251Pro) reduces hepatic steatosis in mice
6. Ceramide synthase 6 (CerS6) is upregulated in alcohol-associated liver disease and exhibits sex-based differences in the regulation of energy homeostasis and lipid droplet accumulation
7. Large-scale identification of undiagnosed hepatic steatosis using natural language processing
8. NAFLD and Cardiovascular and Cardiac Disease: Clinical Implications
9. Effect of omega-3 fatty acids in non-alcoholic fatty liver disease
10. Bile Acids as Emerging Players at the Intersection of Steatotic Liver Disease and Cardiovascular Diseases.
11. A genome-first approach to variants in MLXIPL and their association with hepatic steatosis and plasma lipids.
12. Complications, morbidity and mortality of nonalcoholic fatty liver disease
13. Lipid droplets in steatotic liver disease
14. Growth differentiation factor-15 and the association between type 2 diabetes and liver fibrosis in NAFLD
15. A Missense Variant in Human Perilipin 2 (Plin2 Ser251pro) Reduces Hepatic Steatosis In Mice
16. Aspirin is associated with a reduced incidence of liver disease in men
17. Omega-3 intake is associated with liver disease protection
18. Association of Statin Use With Risk of Liver Disease, Hepatocellular Carcinoma, and Liver-Related Mortality
19. Concomitant western diet and chronic-binge alcohol dysregulate hepatic metabolism
20. Improvement in non-alcoholic fatty liver disease severity is associated with a reduction in carotid intima-media thickness progression
21. Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: Results from the WELCOME trial
22. Sex differences regarding the effect of dietary vitamin E on the liver and metabolic profile.
23. Ceramide synthase 6 (CerS6) promotes alcohol-induced fatty liver by promoting metabolic dysfunction and upregulating lipid droplet-associated proteins
24. Hepatic farnesoid X receptor protein level and circulating fibroblast growth factor 19 concentration in children with NAFLD
25. Nonalcoholic Fatty Liver Disease in Children
26. A coding variant in the microsomal triglyceride transfer protein reduces both hepatic steatosis and plasma lipids.
27. Higher body fat percentage is associated with enhanced temperature perception in NAFLD: results from the randomised Wessex Evaluation of fatty Liver and Cardiovascular markers in NAFLD with OMacor thErapy trial (WELCOME) trial
28. The effects of dietary vitamin E intake on NAFLD and sex differences in serum metabolic profile
29. Tu1300: PERILIPIN2 S251 POLYMORPHISM PROTECTS FROM LIVER TRIGLYCERIDE ACCUMULAITON.
30. 384 ASSOCIATION OF A GLUCAGON-LIKE PEPTIDE-1 RECEPTOR GENE VARIANT WITH METABOLIC DYSFUNCTION ASSOCIATED LIVER DISEASE (MASLD)
31. Impact of high dose n-3 polyunsaturated fatty acid treatment on measures of microvascular function and vibration perception in non-alcoholic fatty liver disease: results from the randomised WELCOME trial
32. Dietary Vitamin E Intake Is Associated With a Reduced Risk of Developing Digestive Diseases and Nonalcoholic Fatty Liver Disease
33. Growth differentiation factor-15 and the association between type 2 diabetes and liver fibrosis in NAFLD.
34. Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials
35. Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: Results from the WELCOME* study
36. The common p.Ile291Val variant of ERLIN1enhances TM6SF2 function and is associated with protection against MASLD
37. EP112 A MISSENSE VARIANT IN HUMAN PERILIPIN2 (PLIN2 SER251PRO) REDUCES HEPATIC STEATOSIS IN MICE
38. A new perspective on NAFLD: Focusing on lipid droplets.
39. Factors independently associated with cardiorespiratory fitness in patients with non‐alcoholic fatty liver disease
40. Liver-specific ceramide reduction alleviates steatosis and insulin resistance in alcohol-fed mice
41. Dysregulated Neurovascular Control Underlies Declining Microvascular Functionality in People With Non-alcoholic Fatty Liver Disease (NAFLD) at Risk of Liver Fibrosis
42. Synbiotics Alter Fecal Microbiomes, But Not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Nonalcoholic Fatty Liver Disease
43. In vitro effects of Bifidobacterium lactis-based synbiotics on human faecal bacteria
44. Multi-domain analysis of microvascular flow motion dynamics
45. Liver zonation in children with NAFLD: associations with dietary fructose and uric acid concentrations
46. Marine omega-3 fatty acid supplementation in non-alcoholic fatty liver disease: Plasma proteomics in the randomized WELCOME* trial
47. Diagnosis and management of non-alcoholic fatty liver disease
48. Rapid Lipid Droplet Isolation Protocol Using a Well-established Organelle Isolation Kit
49. LBP-04-Investigation of synbiotic treatment in non-alcoholic fatty liver disease (NAFLD): Results of the INSYTE study
50. Multi‐domain analysis of microvascular flow motion dynamics in NAFLD
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.